There are several reasons why previously undescribed adverse effects emerge after a drug is marketed. Before a new drug is registered for use it must undergo a rigorous series of clinical trials, but the total number of patients who have been given the drug rarely exceeds 3000 before it is marketed. Inevitably any adverse effect, for example liver toxicity, occurring in fewer than 1 in 1000 people may not be detected until the drug has been more widely used. Secondly, if the drug induces an increase in a common disease, such as myocardial infarction, the effect will only be detected by appropriately designed large trials or epidemiological studies. Thirdly, the duration of early clinical trials rarely exceeds a few weeks or months and the patients included are often atypical of the population which will take the new drug for many years. Pioglitazone and rosiglitazone, the two PPARγ agonists available in Australia, do not cause serious liver damage, but do induce weight gain, fluid retention and heart failure. One study found that over 40 months the incidence of heart failure was 8.2% in patients taking thiazolidinediones compared with 5.3% in a control group. 1 The drugs are therefore contraindicated in patients with heart failure (New York Heart Association class III or IV).
Recent data suggest further associations between glitazones, cardiovascular events 2 and peripheral limb fractures. 3 Pioglitazone and rosiglitazone have been associated with an increase in peripheral fractures in postmenopausal women, particularly in the humerus, hands and feet. There is also a study suggesting that rosiglitazone may reduce bone formation and density. 4 A meta-analysis reported a significant increase in the risk of In Australia, patients being considered for treatment with a glitazone will already be taking metformin, a sulfonylurea or both, and will have poor glycaemic control with or without symptoms. The aim of further lowering of blood glucose concentrations is to reduce the incidence of both macro-and microvascular disease. Even better outcomes can be achieved by additionally improving the control of blood pressure. 7 These goals should have a high priority in all patients, but are the glitazones the best way to achieve them? They have been shown to slow the progression of type 2 diabetes over four years 8 , but this is only a surrogate measure for long-term outcomes.
The alternative therapy in these patients is insulin. This is as These evolving problems with thiazolidinediones reinforce the fact that new is not always better. We do not have all the answers so it will be necessary to modify prescribing as more information becomes available. Consumers can find out how well a medicine works, its side effects, how it compares with other treatments, and who is likely to benefit most. Medicine Update is available online at www.nps.org.au/consumers
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